US5232441A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating schistosomal infestations by iontophoresis
Assignee: PHYSION Srl A CORP OF ITALY
•
Filing: 1992-05-18
•
Granted: 1993-08-03
•
Expires: 2012-05-18
Abstract
Abstract A method of treating schistosomal infestations by both adult worms and eggs-miracidia, residing in the veins, venules and nearby tissues either of the bladder and ureters or of the colorectal regions of the intestines, including the locally administration by iontophoresis of at least an antischistosomal drug in the form of a solution.
Inventors
- 👤 Robert L. Stephen
- 👤 Franco Lugnani
- 👤 Cino Rossi
- 👤 Silvio Eruzzi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 04:24
CPC Classifications
A; A61; A61N; A61N1/00; A61N1/18; A61N1/20; A61N1/30; A61N1/303; A61N1/306
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
155 words
A method of treating schistosomal infestations by both adult worms and eggs-miracidia, localized in the veins, venules and nearby tissues either of the bladder and ureters or of the colo-rectal regions of the intestine which comprises the steps of: a) inserting a catheter via the urethra into the bladder or via rectum within a selected segment of the colo-rectal region, said catheter encompassing an active electrode of appropriate polarity connected to an external power source; b) infusing via said catheter at least an antischistosomal drug in the form of a solution; c) placing in contact with a suitable skin location, an indifferent electrode of opposite polarity to said active electrode; d) supplying an electrical current from said external power source with matching polarities to said active electrode and said indifferent electrode thereby permitting passage of current and consequent administration by iontophoresis of said at least an antischistosomal drug into the tissues surrounding the active electrode.
Claim 2
Independent Claim
155 words
A method of treating schistosomal infestations by both adult worms and eggs-miracidia, localized in the veins, venules and nearby tissues either of the bladder and ureters or of the colo-rectal regions of the intestine which comprises the steps of: a) inserting a catheter via the urethra into the bladder or via rectum within a selected segment of the colo-rectal region, said catheter encompassing an active electrode of appropriate polarity connected to an external power source; b) infusing via said catheter at least an antischistosomal drug in the form of a solution; c) placing in contact with a suitable skin location, an indifferent electrode of opposite polarity to said active electrode; d) supplying an electrical current from said external power source with matching polarities to said active electrode and said indifferent electrode thereby permitting passage of current and consequent administration by iontophoresis of said at least an antischistosomal drug into the tissues surrounding the active electrode.
Claim 3
Dependent Claim
17 words
A method according to claim 1, wherein said at least an antischistosomal drug is an ionizable compound.
Claim 4
Dependent Claim
24 words
A method according to claim 1, wherein said antischistosomal drug is difficulty ionizable and is administered in conjunction with at least another ionizable drug.
Claim 5
Dependent Claim
11 words
A method according to claim 1, comprising administering two antischistosomal drugs.
Claim 6
Dependent Claim
17 words
A method according of claim 1, comprising administering an antischistosomal drug in conjunction with an anti-inflammatory drug.
Claim 7
Dependent Claim
34 words
A method according to claim 1, wherein said antischistosomal drug is selected from the group consisting of a trivalent antimony compound, a pentavalent antimony compound, niridazole, metrifonate, oxamniquine, praziquantel, mixture thereof and salts thereof.
Claim 8
Dependent Claim
24 words
A method according to claim 1, wherein said antischistosomal drug is a trivalent antimony compound selected from salts of trivalent antimony with organic acids.
Claim 9
Dependent Claim
24 words
A method according to claim 1, wherein said antischistosomal drug is a pentavalent antimony compound selected from salts of pentavalent antimony with organic acids.
Claim 10
Dependent Claim
12 words
A method according to claim 1, wherein said antischistosomal drug is niridazole.
Claim 11
Dependent Claim
12 words
A method according to claim 1, wherein said antischistosomal drug is metrifonate.
Claim 12
Dependent Claim
12 words
A method according to claim 1, wherein said antischistosomal drug is oxamniquine.
Claim 13
Dependent Claim
12 words
A method according to claim 1, wherein said antischistosomal drug is praziquantel.
Claim 14
Dependent Claim
18 words
A method according to claim 4, wherein said two drugs are a trivalent and a pentavalent antimony compounds.
Claim 15
Dependent Claim
22 words
A method according to claim 4, wherein said two drugs are either one of a trivalent or pentavalent antimony compound, and metrifonate.
Claim 16
Dependent Claim
22 words
A method according to claim 4, wherein said two drugs are either one of a trivalent or pentavalent antimony compound, and niridazole.
Claim 17
Dependent Claim
22 words
A method according to claim 4, wherein said two drugs are either one of a trivalent or pentavalent antimony compound, and oxamniquine.
Claim 18
Dependent Claim
20 words
A method according to claim 4, wherein said two drugs are either one of a trivalent or pentavalent antimony compound.
Claim 19
Dependent Claim
16 words
A method according to claim 5, wherein said anti-inflammatory drug is an ionized esterified corticosteroid compound.
Claim 20
Dependent Claim
18 words
A method according to claim 5, wherein said anti-inflammatory drug is a corticosteroid compound consisting of dexamethasone phosphate.
Claim 21
Dependent Claim
24 words
A method according to claim 1, wherein said antischistosomal drug is contained in said solution at a concentration ranging from 0.2 to 10% w/v.
Claim 22
Dependent Claim
23 words
A method according to claim 1, comprising administering from 20 to 500 ml of said solution containing said at least one antischistosomal drug.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-08-02 | 1997-02-01 | 1997-08-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-08-02 | 2001-02-01 | 2001-08-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-08-02 | 2005-02-01 | 2005-08-03 | $7700.00 | Window Closed / Lapsed |